GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0734
0.00 (0.00%)
Oct 22, 2026, 5:35 PM CEST
GenSight Biologics Revenue
GenSight Biologics had revenue of -856.00K EUR in the half year ending June 30, 2026. This brings the company's total for the last twelve months to -251.00K. In the year 2025, GenSight Biologics had annual revenue of 652.00K, down -75.16%. That makes GenSight Biologics the 48,081st largest company in the world by revenue and 640th in France.
Revenue (ttm)
-251.00K
Revenue Growth
-75.16%
P/S Ratio
n/a
Revenue / Employee
-13.94K
Employees
18
Market Cap
17.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 652.00K | -1.97M | -75.16% |
| Dec 31, 2024 | 2.63M | -338.00K | -11.41% |
| Dec 31, 2023 | 2.96M | -1.90M | -39.10% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | 7.44M | 2.53M | 51.53% |
| Dec 31, 2019 | 4.91M | 564.00K | 12.98% |
| Dec 31, 2018 | 4.35M | 644.00K | 17.40% |
| Dec 31, 2017 | 3.70M | 701.00K | 23.36% |
| Dec 31, 2016 | 3.00M | -559.00K | -15.70% |
| Dec 31, 2015 | 3.56M | 2.46M | 222.85% |
| Dec 31, 2014 | 1.10M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 24.58M |
| Nicox | 16.77M |
| Fermentalg | 13.20M |
| Advicenne | 10.74M |
| Poxel | 7.66M |
| MaaT Pharma | 3.18M |
| Aelis Farma | 2.19M |
| Aton | 661.00K |
GenSight Biologics News
- 14 days ago - Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa - Business Wire
- 15 days ago - GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders - Business Wire
- 15 days ago - GenSight Biologics Reports Cash Position as of September 30, 2026 - Business Wire
- 15 days ago - GenSight Biologics Earnings release: Q3 2026 - Filings
- 23 days ago - GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates - Business Wire
- 23 days ago - GenSight Biologics Quarterly report: H1 2026 - Filings
- 23 days ago - GenSight Biologics Earnings release: H1 2026 - Filings
- 6 weeks ago - GenSight Biologics Provides Business Update, Sets Results Date; Stock Up - Nasdaq